136 related articles for article (PubMed ID: 33262525)
1. BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS.
Soverini S; Martelli M; Bavaro L; De Benedittis C; Sica S; Sorà F; Iurlo A; Bonifacio M; Pregno P; Galimberti S; Lunghi F; Albano F; D'Adda M; Crugnola M; Capodanno I; Castagnetti F; Gugliotta G; Papayannidis C; Rosti G; Percesepe A; Mignone F; Baccarani M; Martinelli G; Cavo M
Leukemia; 2021 Jul; 35(7):2102-2107. PubMed ID: 33262525
[No Abstract] [Full Text] [Related]
2. Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Soverini S; Martelli M; Bavaro L; De Benedittis C; Papayannidis C; Sartor C; Sorà F; Albano F; Galimberti S; Abruzzese E; Annunziata M; Russo S; Stulle M; Imovilli A; Bonifacio M; Maino E; Stagno F; Maria Basilico C; Borlenghi E; Fozza C; Mignone F; Minari R; Stella S; Baccarani M; Cavo M; Martinelli G
Br J Haematol; 2021 Apr; 193(2):271-279. PubMed ID: 33403687
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.
Soverini S; Albano F; Bassan R; Fabbiano F; Ferrara F; Foà R; Olivieri A; Rambaldi A; Rossi G; Sica S; Specchia G; Venditti A; Barosi G; Pane F
Cancer Med; 2020 May; 9(9):2960-2970. PubMed ID: 32154668
[TBL] [Abstract][Full Text] [Related]
4. Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing.
Szankasi P; Schumacher JA; Kelley TW
Ann Hematol; 2016 Jan; 95(2):201-10. PubMed ID: 26555285
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Zabriskie MS; Eide CA; Tantravahi SK; Vellore NA; Estrada J; Nicolini FE; Khoury HJ; Larson RA; Konopleva M; Cortes JE; Kantarjian H; Jabbour EJ; Kornblau SM; Lipton JH; Rea D; Stenke L; Barbany G; Lange T; Hernández-Boluda JC; Ossenkoppele GJ; Press RD; Chuah C; Goldberg SL; Wetzler M; Mahon FX; Etienne G; Baccarani M; Soverini S; Rosti G; Rousselot P; Friedman R; Deininger M; Reynolds KR; Heaton WL; Eiring AM; Pomicter AD; Khorashad JS; Kelley TW; Baron R; Druker BJ; Deininger MW; O'Hare T
Cancer Cell; 2014 Sep; 26(3):428-442. PubMed ID: 25132497
[TBL] [Abstract][Full Text] [Related]
6. [3rd generation ABL kinase inhibitor and Philadelphia chromosome positive leukemia].
Tauchi T
Rinsho Ketsueki; 2013 Oct; 54(10):1682-6. PubMed ID: 24064817
[No Abstract] [Full Text] [Related]
7. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
[TBL] [Abstract][Full Text] [Related]
8. Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing.
Chen J; Wang F; Fang J; Nie D; Zhang Y; Chen X; Li Y; Tan Y; Ma X; Guo Y; Cao P; Liu M; Liu H
Br J Haematol; 2020 Dec; 191(5):e113-e116. PubMed ID: 33460055
[No Abstract] [Full Text] [Related]
9. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
Machova Polakova K; Kulvait V; Benesova A; Linhartova J; Klamova H; Jaruskova M; de Benedittis C; Haferlach T; Baccarani M; Martinelli G; Stopka T; Ernst T; Hochhaus A; Kohlmann A; Soverini S
J Cancer Res Clin Oncol; 2015 May; 141(5):887-99. PubMed ID: 25367136
[TBL] [Abstract][Full Text] [Related]
10. CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?
Goldman J
Lab Hematol; 2004; 10(3):181-4. PubMed ID: 15529444
[No Abstract] [Full Text] [Related]
11. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
13. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.
Woessner DW; Eiring AM; Bruno BJ; Zabriskie MS; Reynolds KR; Miller GD; O'Hare T; Deininger MW; Lim CS
Leukemia; 2015 Aug; 29(8):1668-75. PubMed ID: 25721898
[TBL] [Abstract][Full Text] [Related]
14. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
15. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.
Soverini S; De Benedittis C; Machova Polakova K; Brouckova A; Horner D; Iacono M; Castagnetti F; Gugliotta G; Palandri F; Papayannidis C; Iacobucci I; Venturi C; Bochicchio MT; Klamova H; Cattina F; Russo D; Bresciani P; Binotto G; Giannini B; Kohlmann A; Haferlach T; Roller A; Rosti G; Cavo M; Baccarani M; Martinelli G
Blood; 2013 Aug; 122(9):1634-48. PubMed ID: 23794064
[TBL] [Abstract][Full Text] [Related]
17. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
18. ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL).
Selle B; Bär C; Hecker S; Schmidt-Rohr U; Viehmann S; Debatin KM; Reinhardt D
Leukemia; 2002 Jul; 16(7):1393-5. PubMed ID: 12094266
[No Abstract] [Full Text] [Related]
19. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.
Ma W; Kantarjian H; Yeh CH; Zhang ZJ; Cortes J; Albitar M
Acta Haematol; 2009; 121(1):27-31. PubMed ID: 19332983
[No Abstract] [Full Text] [Related]
20. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
Soverini S; De Benedittis C; Papayannidis C; Polakova KM; Venturi C; Russo D; Bresciani P; Iurlo A; Mancini M; Vitale A; Chiaretti S; Foà R; Abruzzese E; Sorà F; Kohlmann A; Haferlach T; Baccarani M; Cavo M; Martinelli G
Leukemia; 2016 Jul; 30(7):1615-9. PubMed ID: 26867670
[No Abstract] [Full Text] [Related]
[Next] [New Search]
